BioSpace News Archive

Havn Life Sciences Inc. (CSE:HAVN)(OTC PINK:HAVLF)(FSE:5NP) (the “Company” or “Havn Life”), a biotechnology company pursuing standardized extraction of psychoactive compounds and the development of natural healthcare products, announced today that it will be presenting virtually at the upcoming Zooming with LD event on Wednesday, March 24th 2020 at 8:00 AM PT/11:00 AM ET.

Rising cases of gynecological disorders such as uterine cancers and polycystic ovarian disease to foster the sales of hysteroscopy systems

Growing cases of osteopenia arising out of surging geriatric population is prompting key market players to invest in osteoporosis testing industry

Plasma fractionation is the first process for large-scale protein purification, which was developed about 60 years ago by Cohn and co-workers.

The global industrial microbiology market is growing, thanks to the rising preference for industrial automation across the globe.

MagicMed Industries Inc. (“MagicMed” or the “Company”), a biotechnology company focused on creating novel psychedelic derivative molecules, today announced that Dr. Joseph Tucker, President and Chief Executive Officer, will be presenting a business and pipeline update at the Q1 Virtual Investor Summit on March 24th, 2021

Apollo Endosurgery, Inc. (“Apollo”) (NASDAQ:APEN), a global leader in minimally invasive medical devices for gastrointestinal and bariatric procedures, announced the terms of equity awards granted to Chas McKhann in connection with his appointment as the company’s CEO in March 2021

EarthRenew Inc. (CSE: ERTH; OTCQB: VVIVF) (“EarthRenew” or the “Company”), a Canadian company focused on regenerative agriculture solutions, today announced that its CEO, Keith Driver, will present live at LifeSciencesInvestorForum.com on March 25, 2021.

Arena Pharmaceuticals, Inc. announced that the Compensation Committee of its Board of Directors granted inducement stock options, inducement performance restricted stock units, and inducement restricted stock units to new employees.

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) approved PONVORY™ (ponesimod), a once-daily oral selective sphingosine-1-phosphate receptor 1 (S1P1) modulator, to treat adults with relapsing forms of multiple sclerosis (MS),